tbuckley/cabot-search huggingface dataset:
Randomized phase II trial of two different nutritional approaches for patients receiving treatment for their advanced pancreatic cancer.
Authors: Diana L. Hanna, Gayle S. Jameson, Drew W. Rasco, Angela Tatiana Alistar, Richard C. Frank, Anthony B. El-Khoueiry, Julia Wiedmeier, Caroline Roberts, Brandon Fell, Sarah Hallberg, Denise Roe, Derek Cridebring, Joshua D Rabinowitz, Stephen Gately, Daniel D. Von Hoff
Journal: Journal of Clinical Oncology (2022)

TPS637 Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by stromal fibrosis, hypoxia, and nutritional deprivation. PDAC tumors grow aggressively, diagnosis is typically made after metastasis and the disease remains associated with poor outcomes. The triplet chemotherapy regimen of gemcitabine, nab-paclitaxel with cisplatin was associated with a median overall survival of 16.4 months in patients with metastatic pancreatic cancer in the first-line setting (Jameson et al., 2020). Nutritional, metabolic interventions offer an opportunity to fundamentally change the tumor microenvironment and improve outcomes for patients. A ketogenic diet defined as lower carbohydrate, lower protein, and higher fat can significantly reduce glucose and insulin and increase metabolically active ketone bodies and has been evaluated in patients with a variety of solid tumors (Weber et al, 2020). Recently, a ketogenic diet combined with triplet chemotherapy was shown to inhibit murine pancreatic KPC tumor growth and significantly prolong animal survival over chemotherapy alone. Tumor growth inhibition was associated with glucose depletion, altered TCA substrate usage, and NADH elevation. Methods: In this Phase II randomized clinical trial (NCT04631445), we are evaluating a medically supervised ketogenic diet (MSKD) versus a standard diet when combined with the triplet therapy in patients with treatment-naive advanced pancreatic cancer. The primary endpoint is progression free survival for triplet therapy while on MSKD or non-MSKD. Secondary endpoints include disease control rate (PR+ CR+ SD for at least 9 weeks), change in CA 19-9 (or CA125, or CEA if not expressers of CA 19-9), average insulin levels, HbA1c, body weight, a comparison of gut microbial diversity, changes in serum metabolites and quality of life via the EORTC QLQ-C30 assessment. Unlike prior ketogenic intervention studies, the MSKD is being supported by a continuous care nutrition intervention through Virta Health Corp, that offers tracking of daily ketone and glucose levels, a web-based software application, education, and communication with a remote care team to ensure sustained nutritional ketosis. A total of 40 patients with untreated metastatic PDAC are planned for enrollment, 20 randomized to each arm. The trial opened for accrual November 2020. Clinical trial information: NCT04631445.
Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer’s disease
Authors: Frederic Brosseron, Anne Maass, Luca Kleineidam, Kishore Aravind Ravichandran, Pablo García González, Róisín M. McManus, Christina Ising, Francesco Santarelli, Carl-Christian Kolbe, Lisa M. Häsler, Steffen Wolfsgruber, Marta Marquié, Mercè Boada, Adelina Orellana, Itziar de Rojas, Sandra Röske, Oliver Peters, Nicoleta-Carmen Cosma, Arda Cetindag, Xiao Wang, Josef Priller, Eike J. Spruth, Slawek Altenstein, Anja Schneider, Klaus Fliessbach, Jens Wiltfang, Björn H. Schott, Katharina Bürger, Daniel Janowitz, Martin Dichgans, Robert Perneczky, Boris-Stephan Rauchmann, Stefan Teipel, Ingo Kilimann, Doreen Goerss, Christoph Laske, Matthias H. Munk, Emrah Düzel, Renat Yakupov, Laura Dobisch, Coraline D. Metzger, Wenzel Glanz, Michael Ewers, Peter Dechent, John Dylan Haynes, Klaus Scheffler, Nina Roy, Ayda Rostamzadeh, Charlotte E. Teunissen, Natalie L. Marchant, Annika Spottke, Mathias Jucker, Eicke Latz, Michael Wagner, David Mengel, Matthis Synofzik, Frank Jessen, Alfredo Ramirez, Agustín Ruiz, Michael T. Heneka
Journal: Neuron (2022)
A phase 1b multitumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors (COSMIC-021): Results of the colorectal cancer cohort.
Authors: Thomas Adam Abrams, Syed Mohammad Ali Kazmi, Ira Seth Winer, Vivek Subbiah, Gerald Steven Falchook, Matthew Reilley, Paul Raymond Kunk, Sanjay Goel, Ignacio Garrido-Laguna, Mark D. Kochenderfer, Scott Werneke, Lana Andrianova, Ramu Sudhagoni, Scott Paulson
Journal: Journal of Clinical Oncology (2022)

121 Background: Cabozantinib, a multiple receptor tyrosine kinase inhibitor, promotes an immune-permissive environment which may enhance the activity of immune checkpoint inhibitors. COSMIC-021 (NCT03170960) is evaluating the combination of cabozantinib with atezolizumab, an anti-PD-L1 inhibitor, in patients with advanced solid tumors. Outcomes in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-containing therapy are presented. Methods: Pts with mCRC and an ECOG PS of 0–1 who progressed during or following systemic chemotherapy including fluoropyrimidine plus oxaliplatin or irinotecan were eligible. Up to 2 prior lines of anti-cancer therapy including EGFR-targeted therapy were allowed. Microsatellite instability high (MSI-H) and/or mismatch repair (MMR)-deficient pts were excluded. Pts received cabozantinib 40 mg PO QD plus atezolizumab 1200 mg IV Q3W. The primary endpoint was objective response rate (ORR) per RECIST 1.1 by investigator. Other endpoints included safety, duration of response (DOR), progression-free survival (PFS), and overall survival (OS). CT/MRI scans were performed Q6W for the first year and Q12W thereafter. Results: 31 pts received cabozantinib plus atezolizumab (median age, 60 y [range 31, 79]; male, 58%; ECOG PS 1, 61%; 2 prior lines of therapy, 71%; prior EGFR inhibitor, 16%; ≥3 tumor sites, 52%; tumors in left colorectum, 71%). Median follow-up was 28.1 mo (range, 24.2, 31.3) as of July 21, 2021. Cabozantinib plus atezolizumab demonstrated clinical activity in pts with mCRC (Table). Patients with wild-type RAS (n = 12) had numerically longer PFS and OS and higher ORR vs those with mutations (n = 19) (Table). Treatment-related adverse events (TRAEs) of any grade occurred in 28 (90%); the most common were diarrhea (52%), fatigue (42%), and nausea (35%). Grade 3-4 TRAEs occurred in 16 (52%); the most common were hypertension (10%), fatigue (6%), and lipase increased (6%); no Grade 5 events were reported. Conclusions: Cabozantinib plus atezolizumab demonstrated encouraging clinical activity with manageable toxicity in pts with previously treated advanced non-MSI-H/MMR-proficient CRC. Clinical trial information: NCT03170960. [Table: see text]
Error in the Results and eTable 2 in Supplement 2
Journal: JAMA Network Open (2021)

Hana Kahleova, MD, PhD; Kitt Falk Petersen, MD; Gerald I. Shulman, MD, PhD; Jihad Alwarith, BS; Emilie Rembert, BS; Andrea Tura, PhD; Martin Hill, PhD; Richard Holubkov, PhD; Neal D. Barnard, MD
Klerman's “credo” reconsidered:<scp>neo‐Kraepelinianism</scp>, Spitzer's views, and what we can learn from the past
Authors: Jerome C. Wakefield
Journal: World Psychiatry (2022)

In 1978, G. Klerman published an essay in which he named the then‐nascent “neo‐Kraepelinian” movement and formulated a “credo” of nine propositions expressing the movement's essential claims and aspirations. Klerman's essay appeared on the eve of the triumph of neo‐Kraepelinian ideas in the DSM‐III. However, this diagnostic system has subsequently come under attack, opening the way for competing proposals for the future of psychiatric nosology. To better understand what is at stake, in this paper I provide a close reading and consideration of Klerman's credo in light of the past forty years of research and reflection. The credo is placed in the context of two equally seminal publications in the same year, one by S. Guze, the leading neo‐Kraepelinian theorist, and the other by R. Spitzer and J. Endicott, defining mental disorder. The divergences between Spitzer and standard neo‐Kraepelinianism are highlighted and argued to be much more important than is generally realized. The analysis of Klerman's credo is also argued to have implications for how to satisfactorily resolve the current nosological ferment in psychiatry. In addition to issues such as creating descriptive syndromal diagnostic criteria, overthrowing psychoanalytic dominance of psychiatry, and making psychiatry more scientific, neo‐Kraepelinians were deeply concerned with the conceptual issue of the nature of mental disorder and the defense of psychiatry's medical legitimacy in response to antipsychiatric criticisms. These issues cannot be ignored, and I argue that proposals currently on offer to replace the neo‐Kraepelinian system, especially popular proposals to replace it with dimensional measures, fail to adequately address them.
Possible link probed: deafness and vitamin D
Authors: T. Ziporyn
Journal: JAMA (1983)

Several years ago a 35-year-old Asian man went to the London Hospital with a two-year history of progressive bilateral deafness and tinnitus. Before otolaryngologists there could examine him, however, he was hospitalized for severe frontal headaches and underwent a full blood screen. Later, when otolaryngologist Gerald B. Brookes, MB, FRCS, looked at the results, he noticed that the plasma levels of inorganic phosphate, calcium, and alkaline phosphatase were abnormal, suggesting a bone disorder. "I didn't know what this meant, so I 'phoned up one of our metabolic physicians," recalls Brookes, who reported his work at the Sixth British Academic Conference in Otolaryngology in Bristol, England, during the summer. "He immediately asked me if the patient was Asian. It turns out, you see, that for some reason Asians in Britain are at particular risk for rickets and osteomalacia because of a vitamin D deficiency." Sure enough, when Brookes, senior registrar at
Large-scale manufacturing and characterization of CMV-CD19CAR T cells
Authors: Xiuli Wang, Ryan Urak, Miriam Walter, Min Guan, Tianxu Han, Vibhuti Vyas, Sheng-Hsuan Chien, Brenna Gittins, Mary C Clark, Sally Mokhtari, Angelo Cardoso, Don J Diamond, John Zaia, Stephen J Forman, Ryotaro Nakamura
Journal: Journal for ImmunoTherapy of Cancer (2022)

Adoptive transfer of CD19-specific chimeric antigen receptor (CD19CAR) T cells can induce dramatic disease regression in patients with B cell malignancies. CD19CAR T cell therapy may be limited by insufficient engraftment and persistence, resulting in tumor relapse. We previously demonstrated a proof of principle that cytomegalovirus (CMV)-specific T cells can be isolated and enriched prior to CD19CAR transduction to produce CMV-CD19CAR T cells, and that these CMV-CD19CAR T cells can be expanded in vivo through CMV vaccination, resulting in better tumor control in a murine model. Here we developed a clinical platform for generating CMV-CD19CAR T cells. Peripheral blood mononuclear cells (PBMCs) collected from CMV-seropositive healthy donors were stimulated with a good manufacturing practices-grade PepTivator overlapping CMVpp65 peptide pool and enriched for CMV-responsive interferon γ (IFNγ)+T cells using IFNγ Catchmatrix, within the CliniMACS Prodigy Cytokine Capture System (Miltenyi Biotec). Resulting CMV-specific T cells were transduced with a lentiviral vector encoding a second generation CD19R:CD28:ζ/EGFRt CAR and expanded with interleukin 2 (IL-2) and IL-15 for 15 days before characterization. CMV-specific T cells were enriched from 0.8%±0.5 of input PBMC to 76.3%±11.6 in nine full-scale qualification runs (absolute yield of 4.2±3.3×106 IFNγ+T cells from an input of 1×109 PBMCs). Average CD19CAR transduction efficiency of CMV-specific T cells was 27.0%±14.2 in the final products, which underwent rapid expansion, resulting in a total cell dose of 6.2±0.9 × 106 CD19CAR-tranduced T cells with CMV specificity (ie, functionally bispecific). CMV-CD19CAR T cells were polyclonal, expressed memory markers but had low expression of exhaustion markers, responded to both CD19 and CMVpp65 stimulation with rapid proliferation and exhibited antigen-specific effector functions against both CD19-expressing tumors and CMVpp65 antigen. The final products passed release criteria for clinical use. We demonstrated the feasibility of our large-scale platform for generating CMV-CD19CAR T cells for clinical application. We plan to initiate a clinical trial at City of Hope using CMV-CD19CAR T cells for patients with intermediate/high-grade B cell non-Hodgkin's lymphoma immediately after autologous hematopoietic cell transplantation followed by vaccination with a novel CMV vaccine based on Modified Vaccinia Ankara (Triplex) 28 days and 56 days post-T cell infusion.
Arsenal helps publicise testicular cancer website
Journal: BMJ (2003)

relatively small.Also, patients in the virtual outreach group reported significantly shorter time off work than patients in the standard outpatient group.The trial results provide good evidence that virtual outreach consultations are less time consuming and cheaper for patients and are likely to have a positive impact on productivity.Considering total costs, little justification on economic grounds seems to exist for the adoption of virtual outreach.However, all the benefits may not have been recouped within the six month follow up period, and we did not estimate values of improved patient satisfaction.We may therefore have underestimated the beneficial consequences of virtual outreach.Furthermore, previous subanalysis showed that certain specialties may be more appropriate for virtual outreach than others, 5 and improved selection of patients may also improve the relative cost effectiveness of virtual outreach.We acknowledge the invaluable contribution made by all the participating clinicians and nursing, administrative, and management staff in both the London and Shrewsbury arms of the trial (see bmj.com).Ann Bowling and John Wynn Jones provided valuable input to the design of the study, and we thank Will Coppola for help with extraction of prescription data.The project office in London
Practical Methods in Biochemistry
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Orbital Cowpox
Authors: Miles Kiernan, Nikolaos Koutroumanos
Journal: New England Journal of Medicine (2021)

A 28-year-old woman presented with redness, irritation, and discharge in the right eye. Two weeks before symptom onset, her pet cat had developed lesions on the paws. PCR tests of swabs from the cat’s lesions and the patient’s conjunctiva were performed, and a diagnosis of cowpox was made.
Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont<i>et al</i>
Authors: Jeffrey Weber, Mario Mandala, Paolo Antonio Ascierto, James Larkin
Journal: Journal for ImmunoTherapy of Cancer (2022)

We wish to thank Eggermont et al [1][1] for their thoughtful communication regarding our recently published article, 'Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival'[2][2] The authors appear to suggest that the differing
Increasing pulse pressure contributes to lifetime risk of congestive heart failure Donald M. Lloyd-Jones, Martin G. Larson, Alexa Beiser, Ralph B. D'Agostino, Ramachandran S. Vasan, Emelia J. Benjamin, Daniel Levy. NHLBI's Framingham Heart Study, Framingham, MA, Massachusetts General Hospital, Boston, MA
Journal: Journal of the American College of Cardiology (2001)
Dermatology
Authors: J. G. Smith
Journal: JAMA (1979)

Investigations during the past year may aid in both the understanding and treatment of two major skin problems: psoriasis and acne. <h3>Psoriasis and Dialysis</h3> The serendipitous observation<sup>1</sup>that psoriasis cleared in patients treated with dialysis for end-stage renal disease has only recently begun to receive attention. Patients with psoriasis, with and without impaired renal function, who were treated with either hemodialysis or peritoneal dialysis have also had improvement according to other, independent studies from Missouri,<sup>2</sup>Ohio,<sup>3</sup>Minnesota,<sup>4</sup>and India.<sup>5</sup>Although not all patients with psoriasis respond to dialysis, when they do, a clinical response is usually noted within four weeks of the beginning of treatment; often, complete remission is observed at eight weeks. Some of these remissions have lasted from six to 18 months.<sup>6</sup>However, pustular psoriasis does not appear to respond to dialysis.<sup>2</sup>Preliminary information from two patients suggests that dialysis may
Gastric Cancer
Authors: David E. Lilienfeld, Cedric F. Garagliano, M.P.H., Dr.P.H., Abraham M. Lilienfeld, M.D., M.P.H., D.Sc.
Journal: JNCI Journal of the National Cancer Institute (1976)

Gastric Cancer David E. Lilienfeld, David E. Lilienfeld Department of Biostatistics, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, Maryland 21205 Search for other works by this author on: Oxford Academic PubMed Google Scholar Cedric F. Garagliano, M.P.H., Dr.P.H., Cedric F. Garagliano, M.P.H., Dr.P.H. Department of Epidemiology, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, Maryland 21205 Search for other works by this author on: Oxford Academic PubMed Google Scholar Abraham M. Lilienfeld, M.D., M.P.H., D.Sc. Abraham M. Lilienfeld, M.D., M.P.H., D.Sc. University Distinguished Service Professor of Epidemiology, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, Maryland 21205 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 57, Issue 1, July 1976, Page 9, https://doi.org/10.1093/jnci/57.1.9 Published: 01 July 1976
School Closures During Social Lockdown and Mental Health, Health Behaviors, and Well-being Among Children and Adolescents During the First COVID-19 Wave
Authors: Russell Viner, Simon Russell, Rosella Saulle, Helen Croker, Claire Stansfield, Jessica Packer, Dasha Nicholls, Anne-Lise Goddings, Chris Bonell, Lee Hudson, Steven Hope, Joseph Ward, Nina Schwalbe, Antony Morgan, Silvia Minozzi
Journal: JAMA Pediatrics (2022)

School closures as part of broader social lockdown measures during the COVID-19 pandemic may be associated with the health and well-being of children and adolescents.To review published reports on the association of school closures during broader social lockdown with mental health, health behaviors, and well-being in children and adolescents aged 0 to 19 years, excluding associations with transmission of infection.Eleven databases were searched from inception to September 2020, and machine learning was applied for screening articles. A total of 16 817 records were screened, 151 were reviewed in full text, and 36 studies were included. Quality assessment was tailored to study type. A narrative synthesis of results was undertaken because data did not allow meta-analysis.A total of 36 studies from 11 countries were identified, involving a total of 79 781 children and adolescents and 18 028 parents, which occurred during the first wave of the COVID-19 pandemic (February to July 2020). All evaluated school closure as part of broader social lockdown during the first COVID-19 wave, and the duration of school closure ranged from 1 week to 3 months. Of those, 9 (25%) were longitudinal pre-post studies, 5 (14%) were cohort, 21 (58%) were cross-sectional, and 1 (3%) was a modeling study. Thirteen studies (36%) were high quality, 17 (47%) were medium quality, and 6 (17%) were low quality. Twenty-three studies (64%) were published, 8 (22%) were online reports, and 5 (14%) were preprints. Twenty-five studies (69%) concerning mental health identified associations across emotional, behavioral, and restlessness/inattention problems; 18% to 60% of children and adolescents scored above risk thresholds for distress, particularly anxiety and depressive symptoms, and 2 studies reported no significant association with suicide. Three studies reported that child protection referrals were lower than expected number of referrals originating in schools. Three studies suggested higher screen time usage, 2 studies reported greater social media use, and 6 studies reported lower physical activity. Studies on sleep (10 studies) and diet (5 studies) provided inconclusive evidence on harms.In this narrative synthesis of reports from the first wave of the COVID-19 pandemic, studies of short-term school closures as part of social lockdown measures reported adverse mental health symptoms and health behaviors among children and adolescents. Associations between school closure and health outcomes and behaviors could not be separated from broader lockdown measures.
index to advertisers
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal